# CRISPR Therapeutics

Type: Company (CRSP)

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/crispr-therapeutics
Canonical HTML page: https://getfinancebrief.com/entity/crispr-therapeutics

## Timeline

- **2026-03-11**: Offering Upsized — The company prices an upsized $550M offering due to strong institutional interest.
- **2026-03-11**: ARK Invest Trade — Cathie Wood's ARK Invest buys the dip, increasing its position in CRSP shares.
- **2026-03-10**: Debt Offering Announced — CRISPR Therapeutics announces a $350M convertible senior notes offering, causing a stock price dip.

## Recent coverage (2 stories)

### CRSP: 2 Catalysts to Watch in Final 4 Months of 2026
2026-09-03 00:53:29 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

CRISPR Therapeutics has lagged the broader market in 2026, but Casgevy's label expansion and upcoming clinical readouts create two discrete catalysts that could re-rate the stock. Downside risk remains from slow uptake and high cost.
Full story: https://getfinancebrief.com/story/crispr-crsp-catalysts-casgevy-readouts-finance

### Cathie Wood Capitalizes on CRISPR Therapeutics Dip Amid $550M Debt Offering
2026-03-11 11:51:33 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

ARK Invest founder Cathie Wood has increased her stake in CRISPR Therapeutics following a stock price decline triggered by a significant convertible debt offering. The move underscores Wood's long-term conviction in the gene-editing sector despite short-term market volatility and capital-raising pressures.
Full story: https://getfinancebrief.com/story/cathie-wood-buys-crispr-therapeutics-dip

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.